副甲状腺腫瘍の臨床研究の現状と展望 --- 内分泌腫瘍(第2版)ー基礎・臨床研究のアップデートー


[The pathology, diagnosis and therapy on osteoporosis].

The increase of elderly population in Japan suggests the importance of the prevention of osteoporotic fracture. Falls and fractures account for around 10% of the causes for requiring care services in Japan. The Japanese criteria for initiating pharmacological treatment to prevent fragility fracture were revised in 2011. There are many kinds of anti-osteoporosis drugs including bisphosphonates, SERM, teriparatide, and denosumab that have been proven to reduce fractures. Thus, it is important to select drugs appropriate for each osteoporotic patients considering the mechanisms of drug action, their efficacy and side effects. In this article, we review pathophysiology, diagnosis and treatment of osteoporosis.

Nihon Rinsho. Japanese Journal of Clinical Medicine


骨粗鬆症の病態，診断，治療

骨粗鬆症の病態，診断，治療


チアマゾール --- 甲状腺機能異常治療薬

チアマゾール --- 甲状腺機能異常治療薬


レボチロキシンナトリウム --- 甲状腺機能異常治療薬

レボチロキシンナトリウム --- 甲状腺機能異常治療薬


テリパラチド(遺伝子組換え，合成) --- 骨粗鬆症治療薬

テリパラチド(遺伝子組換え，合成) --- 骨粗鬆症治療薬


ラロキシフェン --- 骨粗鬆症治療薬

ラロキシフェン --- 骨粗鬆症治療薬


エルデカルシトール --- 骨粗鬆症治療薬

エルデカルシトール --- 骨粗鬆症治療薬


ミノドロン酸水和物 --- 骨粗鬆症治療薬

ミノドロン酸水和物 --- 骨粗鬆症治療薬


リセドロン酸ナトリウム --- 骨粗鬆症治療薬

リセドロン酸ナトリウム --- 骨粗鬆症治療薬


アレンドロ酸ナトリウム --- 骨粗鬆症治療薬

アレンドロ酸ナトリウム --- 骨粗鬆症治療薬


骨粗鬆症・甲状腺機能異常治療薬

骨粗鬆症・甲状腺機能異常治療薬


インスリン注射により生じた皮下硬血を有する患者の実態調査とその介入の有用性の検討


[Bone Structural Properties and Bone Strength. Bone architecture and strength on unloading].

The bone loss due to space flight or prolonged bed rest observes early stage of unloading and causes both decreased bone formation and increased bone resorption. Mechanical unloading induced not only both tarbecular and cortical bone loss but also greater decline bone structure in weight-bearing bone. These findings and further examination concern about pathophysiolosy will allow for better understanding of unloading-associated bone loss and for development of effective countermeasures.


新しい骨粗鬆症治療薬 --- エルデカルシトール

新しい骨粗鬆症治療薬 --- エルデカルシトール


現在開発中あるいは今後開発される予定の骨粗鬆症治療薬にはどのようなものがありますか?


[Space flight/bedrest immobilization and bone. Bisphosphonate and the loss of bone mineral due to space flight or prolonged bed rest].

Bone mass and strength are maintained by appropriate weight bearing. The loss of bone mineral due to space flight or prolonged bed rest has been recognized by space scientists and physicians. In spite of the wealth of knowledge obtained thus far, many questions remain unanswered regarding the mechanism of bone loss as well as the factors affecting these skeletal processes. Bisphosphonates have a potential to become countermeasures against space flight-induced or disuse osteoporosis. In this review, the effect and the possible role of biphosphonates on the prevention and treatment of unloading-induced osteoporosis are summarized and future prospects are discussed.


内分泌代謝専門医ガイドブック

内分泌代謝専門医ガイドブック


活性型ビタミンD3およびその誘導体

活性型ビタミンD3およびその誘導体


Effect of vitamin D on bone and immune system

ビタミンDの骨と免疫への作用

Journal of Clinical and Experimental Medicine


新規活性型ビタミンD誘導体エルデカルシトールの副作用としての高Ca血症・高Ca尿症の頻度や程度は従来の活性型ビタミンD3製剤とは違いますか?

ファーマナビゲーター 活性型ビタミンD3製剤編

ファーマナビゲーター 活性型ビタミンD3製剤編


エルデカルシトールの使用上の注意点

エルデカルシトールの使用上の注意点

ファーマナビゲーター 活性型ビタミンD3製剤編

ファーマナビゲーター 活性型ビタミンD3製剤編


エルデカルシトールの開発の経緯

エルデカルシトールの開発の経緯

ファーマナビゲーター 活性型ビタミンD3製剤編

ファーマナビゲーター 活性型ビタミンD3製剤編


活性型ビタミンD3製剤の治療上の注意点

活性型ビタミンD3製剤の治療上の注意点

ファーマナビゲーター 活性型ビタミンD3製剤編

ファーマナビゲーター 活性型ビタミンD3製剤編


ファーマナビゲーター 活性型ビタミンD3製剤編

ファーマナビゲーター 活性型ビタミンD3製剤編


Effects of Statins on Cardiorenal Syndrome.

Cardiovascular disease and renal disease have a close relationship that forms a vicious cycle as a cardiorenal syndrome (CRS). Oxidative stress, endothelial dysfunction, and vascular inflammation could be therapeutic targets when the renin-angiotensin-aldosterone system is activated by accumulation of conventional cardiovascular risk factors; however, a strategy for management of CRS has not been established yet. Statins, HMG-CoA reductase inhibitors, have not only cholesterol-lowering effects but also pleiotropic effects on cardiovascular systems, including anti-inflammatory and antioxidant effects and improvement of nitric oxide bioavailability. Since recent studies have indicated that statins have beneficial effects on chronic kidney disease and heart failure as well as coronary artery disease in cholesterol-lowering-dependent/independent manners, treatment with statins might be a successful strategy for preventing deterioration of CRS.

International Journal of Vascular Medicine


[New approved drugs for osteoporosis in Japan].

These 2 years, we had had new therapeutic options for osteoporotic patients, for example minodoronate, bazedoxifene, teriparatide and eldecalcitol in Japan. Minodoronate and eldecalcitol came from Japan and they had many clinical evidences on Japanese patients. Teriparatide is a powerful anabolic agent for bone, had been provided as daily or weekly subcutaneous injection. These reagents may become helpful drug for osteoporotic patients. This review shows the character and clinical evidences of these drugs.


Effects of androgens on cardiovascular remodeling.

Androgens, the male sex hormones, exert various biological effects on many target organs through the transcriptional effects of the nuclear androgen receptor (AR). ARs are expressed not only in classical target organs, such as the brain, genital organs, bone, and skeletal muscles, but also in the cardiovascular system. Because the female sex hormones estrogens are well known to protect against cardiovascular disease, sex has been considered to have a significant clinical impact on cardiovascular mortality. However, the influence of androgens on the cardiovascular system has not been fully elucidated. To clarify this issue, we analyzed the effects of administration of angiotensin II and doxorubicin, an anticancer agent, in a loading model in male wild-type and AR-deficient mice. In this review, we focus on the actions of androgens as potential targets for the prevention of cardiovascular diseases in males.


The Japanese journal of clinical and experimental medicine


骨粗鬆症治療薬としてのビタミンD製剤の位置づけ-新規薬剤の承認を受けて

骨粗鬆症治療薬としてのビタミンD製剤の位置づけ-新規薬剤の承認を受けて


がん治療における骨の管理の重要性 がん骨転移治療 ビスフォスフォネート治療によるBone Management

先端医学者 高橋俊二 編集

先端医学者 高橋俊二 編集


[Frontiers in vitamin D; basic research and clinical application. Eldecalcitol: the effect on bones and calcium metabolism].

Eldecalcitol is a new active vitamin D compound, bearing a hydroxypropyloxy residue at the 2-position of 1, 25 (OH) D . In ovariectomized rats, eldecalcitol increased vertebral bone mass and bone strength by inhibiting bone resorption and maintaining bone formation. In randomized, placebo-controlled, double-blinded clinical trial for osteoporotic subjects, eldecalcitol increased lumber vertebral and hip bone mineral density independent of vitamin D status. Furthermore, in patients with osteoporosis, eldecalcitol treatment was associated with a lower risk of vertebral and wrist fractures, with greater decrease in bone turnover markers compared with alfacalcidol. The incidence of adverse events was similar between the two treatments. Therefore, eldecalcitol can become a new treatment of choice for osteoporosis.


医学スーパーラーニングスリーズ 内分泌・糖尿病内科学

医学スーパーラーニングスリーズ 内分泌・糖尿病内科学


Progress and perspectives in bone research

Nihon Rinsho. Japanese Journal of Clinical Medicine


癌と関連した高カルシウム血症

癌と関連した高カルシウム血症


Parathyroid neoplasms: a state and view of clinical research

副甲状腺腫瘍の臨床研究の現状と展望


ビタミンD新規合成誘導体の展望

ビタミンD新規合成誘導体の展望


電解質異常の診断の進め方-Ca, P, Mg-

電解質異常の診断の進め方-Ca, P, Mg-


ED-71 is a new vitamin D receptor ligand, bearing a hydroxypropoxy substituent at the 2β-position of 1α, 25 (OH) (2)D(3). In ovariectomized rats, ED-71 increased vertebral bone mass and bone strength by inhibiting bone resorption and maintaining bone formation. In randomized, placebo-controlled, double-blinded clinical trial for osteoporotic subjects, ED-71 increased lumber vertebral and hip bone mineral density independently vitamin D status. Furthermore, ED-71 may have a better osteoprotective effect than alfacalcidol and suggest that ED-71 may serve as a new generation of active vitamin D with anti-fracture efficacy in osteiporotic subjects.


Transforming Growth Factor-1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome.

Transforming growth factor-1 (TGF-1) is a polypeptide member of the transforming growth factor superfamily of cytokines. It is a secreted protein that performs many cellular functions including control of cell growth, cell proliferation, cell differentiation and apoptosis. In the cardiovascular system, TGF-1 plays pivotal roles in the pathogenesis of hypertension, restenosis after percutaneous coronary intervention, atherosclerosis, cardiac hypertrophy and heart failure. In addition, TGF-1 has been shown to be increased in adipose tissue of obese subjects with insulin resistance. Furthermore, TGF-1 is a potent initiator of proliferation of renal mesangial cells leading to chronic kidney disease. Some currently available agents can manipulate TGF-1 expression leading to amelioration of cardiovascular diseases. Thus, an understanding of interactions between chronic kidney disease and metabolic syndrome and the development of cardiovascular diseases is an important issue, and attention should be given to TGF-1 as a crucial factor for regulation and modulation of those pathological conditions.


[Secondary osteoporosis UPDATE. Drugs under development for metabolic bone disease].

For the treatment of osteoporosis, anti-resorptive agents including bisphosphonates and raloxifene are widely used. As new anti-resorptive drugs, anti-RANKL antibody and cathepsin K inhibitor are under development. Among bone anabolic agents, daily subcutaneous injection of teriparatide will soon become available in Japan. In addition, new anabolic agents such as calcilitycs and anti-sclerostin antibody are under clinical or preclinical development for the treatment of osteoporosis.


Drugs for osteoporosis under development


電解質異常の診断の進め方ーCa, P, Mg-

電解質異常の診断の進め方ーCa, P, Mg-


Heparin Cofactor II as a Novel Vascular Protective Factor Against Atherosclerosis.

Heparin cofactor II (HCII) specifically inhibits thrombin action at the site of vascular wall injury. We encountered a congenital HCII deficiency patient with advanced multiple atherosclerotic lesions. This patient led us to conduct clinical studies to examine the role of HCII against atherosclerosis. We found that the incidence of in-stent restenosis after percutaneous coronary intervention, severity of carotid atherosclerosis and prevalence of peripheral arterial disease are inversely associated with plasma HCII activity. In order to clarify the vascular protective action of HCII, we generated HCII- deficient mice by gene targeting. In contrast to a previous study, HCII(-/-) mice were embryonically lethal. In HCII(+/-) mice, accelerated intimal hyperplasia and frequent thrombosis were observed after cuff or wire injury of femoral arteries. The number of protease-activated receptor-1 (PAR-1) -positive cells and the gene expression levels of inflammatory cytokines and chemokines were increased in the thickened vascular walls of HCII(+/-) mice. The accelerated intimal hyperplasia in HCII+/- mice with vascular injury was attenuated by human HCII administration. Furthermore, HCII deficiency exaggerated aortic plaque formation with increased oxidative stress in apolipoprotein E(-/-) mice. These results demonstrate that HCII protects against thrombin-induced vascular remodeling in both humans and mice and suggest that HCII is a predictive biomarker and therapeutic target for atherosclerosis.

Journal of Atherosclerosis and Thrombosis


メタボリックシンドロームと骨粗鬆症

メタボリックシンドロームと骨粗鬆症

Keywordで学ぶメタボリックシンドローム

Keywordで学ぶメタボリックシンドローム


Vitamin D-vitamin D receptor system regulates antithrombogenicity in vivo.

Although it has been well documented that vitamin D receptor (VDR) activation influences the expression of various genes involved in calcium homeostasis and cell differentiation, the physiological role of VDR action in hemostasis remains unclear. We studied thrombogenicity in normocalcemic VDR knock-out (KO) mice on a high calcium diet in comparison with that in wild-type mice and that in hypocalcemic VDRKO mice fed a regular diet. Platelet aggregation was significantly enhanced in normocalcemic VDRKO mice. Aortic endothelial nitric-oxide (NO) synthase expression and urinary NOx excretion were reduced in hypocalcemic VDRKO mice but not in normocalcemic VDRKO mice. The gene expression of antithrombin in the liver and that of thrombomodulin in the aorta, liver and kidney were down-regulated in hypo- and normocalcemic VDRKO mice, whereas tissue factor gene expression in the liver and kidney was up-regulated in VDRKO mice regardless of plasma calcium level. Furthermore, VDRKO mice manifested an exacerbated multi-organ thrombus formation after exogenous lipopolysaccharide injection regardless of the calcemic conditions. These results demonstrate that the vitamin D-VDR system plays a pivotal role in antithrombogenicity in vivo.


トピックス: メタボリックシンドロームと骨粗鬆症

トピックス: メタボリックシンドロームと骨粗鬆症


【慢性心不全の分子機構 新しい治療戦略を求めて】 性ステロイドと心保護作用

【慢性心不全の分子機構 新しい治療戦略を求めて】 性ステロイドと心保護作用


血管内皮細胞に対するステロイドの影響と大腿骨頭壊死

血管内皮細胞に対するステロイドの影響と大腿骨頭壊死


検査値異常から読む病態と診断計画 --- 第2章 疾患における病態へのアプローチと診断計画 Ⅷ.内分泌・代謝性疾患 4.尖端巨大症


癌遺伝子と癌抑制遺伝子 ヒト癌と癌遺伝子・癌抑制遺伝子 --- 内分泌癌

癌遺伝子と癌抑制遺伝子 ヒト癌と癌遺伝子・癌抑制遺伝子 --- 内分泌癌


ホルモン受容機構異常に関する調査研究 平成22年度 研究報告書

ホルモン受容機構異常に関する調査研究 平成22年度 研究報告書

厚生労働科学研究費補助金(難治疾患克服研究事業)

厚生労働科学研究費補助金(難治疾患克服研究事業)